Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus
An escalating pandemic of the novel SARS-CoV-2 virus is impacting global health, and effective antivirals are needed. Umifenovir (Arbidol) is an indole-derivative molecule, licensed in Russia and China for prophylaxis and treatment of influenza and other respiratory viral infections. It has been sho...
Main Authors: | Irina Leneva, Nadezhda Kartashova, Artem Poromov, Anastasiia Gracheva, Ekaterina Korchevaya, Ekaterina Glubokova, Olga Borisova, Anna Shtro, Svetlana Loginova, Veronika Shchukina, Ravil Khamitov, Evgeny Faizuloev |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/8/1665 |
Similar Items
-
Umifenovir and coronavirus infections: a review of research results and clinical practice
by: I. A. Leneva, et al.
Published: (2020-12-01) -
In Silico Design of Peptide-Based SARS-CoV-2 Fusion Inhibitors That Target WT and Mutant Versions of SARS-CoV-2 HR1 Domains
by: Shana V. Stoddard, et al.
Published: (2021-07-01) -
Antioxidant Potential of Antiviral Drug Umifenovir
by: Elena V. Proskurnina, et al.
Published: (2020-03-01) -
Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
by: Chang Chen, et al.
Published: (2021-09-01) -
SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01)